Health Blueprint

Back to Longevity News

News summary

Hims & Hers adds Lilly's Zepbound and oral Foundayo

Source: Longevity Docs News • Published: 09 Nov 2026, 00:00

Summarized by Masters of Longevity from Longevity Docs News.

Hims & Hers will prescribe Lilly’s Zepbound and Foundayo at set self-pay prices.

Hims & Hers adds Lilly's Zepbound and oral Foundayo
Key Takeaways
  • Lilly reported self-pay pricing starting at $299 and $149.
  • Hims & Hers is shifting from compounded semaglutide to branded incretins.
  • This partnership has not established clinical outcome benefits yet.
Read the full article at Longevity Docs News ↗

Continue exploring

Recommended MoL Picks

MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.